irinotecan has been researched along with hydroxychloroquine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, X; He, Q; Li, M; Liu, Y; Sheng, Q; Shi, K; Wang, Y; Yu, Q; Zhang, Z | 1 |
1 review(s) available for irinotecan and hydroxychloroquine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for irinotecan and hydroxychloroquine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Synergistic cytotoxicity and co-autophagy inhibition in pancreatic tumor cells and cancer-associated fibroblasts by dual functional peptide-modified liposomes.
Topics: Animals; Antineoplastic Agents; Autophagy; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Disease Progression; Female; Fibrosis; Humans; Hydroxychloroquine; Irinotecan; Liposomes; Mice; Mice, Nude; Nanomedicine; Neoplasm Metastasis; Neoplasm Transplantation; NIH 3T3 Cells; Paclitaxel; Pancreatic Neoplasms; Peptides; Wound Healing | 2019 |